VANI - Vivani Medical, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
EmeryVille,
United States
Type: Equity
VANI price evolution
VANI
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $21.4 | $26.34 | $31.5 | $23.06 |
| Long term investments | ||||
| Property, plant & equipment | $20.03 | $20.51 | $20.9 | $21.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $42.9 | $48.22 | $53.79 | $45.8 |
| Current liabilities | ||||
| Accounts payable | $0.81 | $0.65 | $0.57 | $0.54 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $6.27 | $5.78 | $6.14 | $5.72 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $24.56 | $24.4 | $25.08 | $25.04 |
| Shareholders' equity | ||||
| Retained earnings | -$115.87 | -$109.83 | -$104.48 | -$98.44 |
| Other shareholder equity | $0.09 | $0.06 | $0.09 | $0.14 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $23.06 | $47.53 | $70.51 | $4.27 |
| Long term investments | ||||
| Property, plant & equipment | $21.34 | $1.96 | $0.35 | $0.17 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $45.8 | $51.13 | $70.88 | $4.46 |
| Current liabilities | ||||
| Accounts payable | $0.54 | $1.18 | $0.52 | $0.49 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.72 | $6.82 | $2.46 | $5.13 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $25.04 | $6.82 | $2.51 | $5.13 |
| Shareholders' equity | ||||
| Retained earnings | -$98.44 | -$72.79 | -$328.59 | -$319.66 |
| Other shareholder equity | $0.14 | $0.04 | -$0.38 | -$0.45 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5.68 | $6.23 | $6.22 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$5.36 | -$6.04 | -$6.03 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | $0.13 | $0.5 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $26.96 | $21.24 | $9.06 | $13.17 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.01 | $0.02 | ||
| Net income | ||||
| Net income | -$25.65 | -$13.89 | -$8.92 | -$14.88 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.26 | -$0.22 | -$0.18 | -$0.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $14.23 | $13.8 | $13.69 | $0.13 |
| Effect of exchange rate | -$0 | -$0 | $0 | |
| Change in cash and equivalents | -$1.01 | $4.26 | $8.99 | -$24.45 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.89 | -$0.34 | -$0.01 | $0.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.13 | $63.39 | $75.62 | $8.6 |
| Effect of exchange rate | $0 | $0.01 | ||
| Change in cash and equivalents | -$24.45 | $44.26 | $66.42 | -$8.14 |
News
Fundamentals
| Market cap | $66.87M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 55.27M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.41 |
| Quick ratio | N/A |